Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare form of cancer for which early detection can greatly boost survival, takes on average six years, because the skin rashes associated with it are difficult to interpret.
Continue reading
Scailyte is among the ten selected young science-based university spinoff companies that showcase their visions and strategies in the final rounds of a new award created by Nature Research and Merck.
Continue reading
Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to further advance its biomarker discovery platform.
Continue reading
Scailyte and CHU Rennes have made an initial discovery of a single-cell
Continue reading
ScailyteTM is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to
discover novel and ultra-sensitive biomarkers from single-cell data.
Scailyte ranked among the top100 Swiss startups in 2019. We are unlocking the full potential of Single-Cell Data, which will drive breakthrough discovery in healthcare.
Continue reading
Modern medicine is looking for markers that provide early warning of complex diseases. In its quest to discover these “biomarkers”, the ETH spinoff Scailyte has developed software capable of analysing millions of single cells very efficiently.
Continue reading
Erstmals hat die deutschsprachige Forbes eine Liste der 30 vielversprechendsten Start-ups aus Deutschland, Österreich und der Schweiz (DACH) aus den Bereichen Künstliche Intelligenz und Machine Learning zusammengestellt.
Continue reading
Scailyte closes seed round. Scailyte develops artificial intelligence (AI) based software for best-in-class analysis.
Continue reading
MassChallenge Switzerland awarded CHF 500K in zero equity cash prizes to eight startups in the program’s 2018 cohort.
Continue reading
